Physiomics plc (AIM: PYC) Awarded Multiple New Contracts - Share Talk

Physiomics plc (AIM: PYC) Awarded Multiple New Contracts

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that so far this month, it has secured multiple new contract awards with a combined value of over £345,000.

Why Physiomics Could Be Entering A New Phase Of Commercial Growth

The awards comprise a combination of new and follow-on engagements with respected UK and international biotechnology and oncology-focused organisations, including a NASDAQ-listed clinical-stage biotechnology company, clinical-stage therapeutics developers, and leading cancer research groups. The contracts further reinforce Physiomics’ growing reputation as a trusted scientific partner across the biotech and pharmaceutical sectors.

The projects will utilise the Company’s expertise across modelling and simulation, biometrics and data science to support key stages of drug development, including Phase 1 and 2 clinical data analysis, first-in-human dose selection and ongoing clinical programme support. Several of these projects are expected to commence imminently, and provide revenue through to the end of 2027, thus providing near-term revenue and medium-term revenue visability. The Board believes these contract awards also serve to demonstrate the increasing depth and quality of the Company’s client relationships.

Dr Peter Sargent, CEO of Physiomics, commented: “We are delighted to have secured these contract awards. They reflect our continued investment in business development and marketing, as well as the team’s success in expanding and diversifying our pipeline. These opportunities further strengthen our order book and improve revenue visibility across the business. Our broader pipeline remains strong and we’re excited about a number of additional opportunities that we hope to be able to announce soon”.

Hayley Close, Head of Business Development, added: “We are very pleased to have been awarded these new contracts which include both new and existing clients. The continued expansion of our client network, including engagement with larger international companies, reflects the strengthening of our scientific reputation, development of successful long-term relationships and growing awareness of Physiomics within the biotech and pharmaceutical sectors.”

ENDS

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc

Mike Whitlow

 

Email:  info@physiomics.co.uk


Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned